PharmaCom BioVet, Inc. Announces World's First Dedicated Veterinary Canine Bone Marrow Transplant Center

PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce they are actively formalizing an academic/industry collaboration with the Department of Clinical Sciences, College of Veterinary Medicine at Washington State University to form the world's first dedicated veterinary canine bone marrow transplant center.

The collaboration offers a unique opportunity to establish and maintain a state of the art canine cancer treatment facility for bone marrow transplants, specifically treating lymphoma, which comprises approximately 24% of all canine cancers.

The expertise and experience of Washington State University's Clinical Oncology Program, the facilities at WSU and the support of associative research institutions uniquely positions PharmaCom BioVet to serve a significant population of canine lymphoma patients that may benefit from this level of treatment which is already standard of care in humans.

"PharmaCom BioVet, Inc. is excited about this collaborative effort," said Gary Berthold, Founder and President of PharmaCom BioVet, Inc. "With the establishment of this first dedicated center we will formulate a template for PharmaCom BioVet to establish multiple Bone Marrow Transplant centers across the country. It is our hope that this relationship will also form a model to enable PharmaCom BioVet, Inc. to introduce other types of cancer treatments, procedures, and novel therapeutics."

PharmaCom BioVet seeks to further the opportunities available to people who have encountered cancer in their companion animals and to offer their animals a better quality of life and longevity. In response to demand and the current lack of adequate cancer treatment options and facilities for animal lovers whose pets are suffering from cancer, PharmaCom BioVet intends to open a network of companion animal cancer care centers throughout North America.

About PharmaCom BioVet, Inc.:

PharmaCom BioVet, Inc. is dedicated to advancing the Veterinary care industry for companion animals by establishing state-of-the-art treatment centers for lymphoma and other forms of cancer throughout the country. The purpose of these centers is to help prolong the quality of life for companion animals with cancer and pursue the potential for complete cure. These centers will also operate under the philosophy of providing a compassionate care environment for both companion animal patients and their owners. For more information, please visit our website www.PharmaComBioVet.com.

DISCLOSURE:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.